Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Takeda, Cell Genesys Halt Phase III Trial Of Cancer Vaccine

This article was originally published in PharmAsia News

Executive Summary

U.S.-based Cell Genesys and Japanese partner Takeda Pharmaceutical have stopped a Phase III trial of GVAX, a vaccine they co-developed to prevent prostate cancer. Cell Genesys acted after deaths of trial participants given GVAX exceeded by 20 the number of those on a placebo. The company said it had not identified the cause of the deaths. A spokesman said the firm was reviewing the matter with Takeda and considering a possible change in the business operations between the two partners. (Click here for more

You may also be interested in...

Future Of ESAs In Oncology Uncertain After Takeda Stops Development Of Hematide For CIA

US Government Drug Pricing ‘Negotiation:’ Where We Go From Here

House passes Democratic bill authorizing the federal government to negotiate drug prices in Medicare. While the exercise has sharpened the debate over how prices feed innovation, the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Our table highlights the key provisions of HR 3 and other pending pricing legislation.

Interim Eudamed Scheme: Early SRN Access To Aid Voluntary Actor Registration

The new Eudamed database may be delayed for two years, but the European Commission wants to allow early access to Single Registration Numbers before Eudamed goes live in 2022 to aid voluntary registration in the interim.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts